

---

# New strains for polio vaccines

Andrew Macadam

National Institute for Biological Standards and Control

UK

---

---

## Ideal characteristics of new strains

	OPV	IPV
■ Yield in cell culture	+	+
■ Immunogenicity	+	+
■ Infectivity <i>in vivo</i>	+	-
■ Attenuation	+	(+)
■ Transmission	- ?	-
■ Genetic stability	+	+

---

---

# Recent approaches to new vaccines


	<b>Potential use</b>
■ Intergeneric 5'ncr recombinants <ul style="list-style-type: none"><li>□ Gromeier et al, 2000; Chumakov et al, 2001</li></ul>	Therapeutic, IPV
■ Genetic stabilisation of domain V <ul style="list-style-type: none"><li>□ Macadam et al, 2006; unpublished</li></ul>	OPV, IPV
■ Synonymous codon deoptimisation <ul style="list-style-type: none"><li>□ Burns et al, 2006; Mueller et al, 2006</li></ul>	OPV, IPV
■ Replication fidelity <ul style="list-style-type: none"><li>□ Andino, unpublished</li></ul>	OPV, IPV

---


# Why domain V?

Attenuating residues in this region:


- reduce infectivity in the human gut
- lower growth temperatures
- act through RNA structure so:
  - biological properties can be altered predictably
    - in a genetically stable way
- inhibit translation initiation




# Design



# Temperature-dependence of virus replication in cell culture



## Vero cells



---

# Infectivity *in vivo*


Virus	PD <sub>50</sub> <i>i.s.</i> /log <sub>10</sub> CCID <sub>50</sub>
Sabin 1	2.25
S18/1	> 8.6 (1/16)*
Mahoney	≤ 0.7
Sabin 2	6.4
S18/2	> 8.1 (0/8)*
Sabin 3	3.6
S15	3.7
S17	> 7.1 (4/16)*
S18	> 8.4 (0/16)*
S19	> 8.2 (0/16)*
Leon	0.7

\* paralysed/total at highest dose


---

# One-step growth at 33°C

## HEp2C cells



## Vero cells





---

# Stability

- Selection
    - Passage at supra-optimal temperature
    - Cloning at supra-optimal temperature
  - Phenotypic changes
    - Partial loss of temperature sensitivity (Vero cells)
    - No increase in infectivity *in vivo*
  - Genotypic changes
    - Domain V sequence stable
    - Substitutions selected in protease 2A (Vero cells)
-

---

## Potential applications of self-containing viruses

- S19, S19/1 & S19/2 could be used as laboratory reagents in HEp2C cell based assays
  - S18, S18/1 & S18/2 or S18/Mahoney-P1, S18/MEF-P1 & S18/Saukett-P1 (under construction) could be used for IPV production in Vero cells
-